mounjaro eli lilly - Search News

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.

Business Insider · 16h

Eli Lilly And Co. Q4 Profit Increases, Beats Estimates

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The

invezz on MSN · 11h

Why did Eli Lilly report mixed Q4 results despite soaring demand for Zepbound and Mounjaro?

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and diabetes treatment Mounjaro continued to soar.

AOL · 14h

Eli Lilly reports mixed earnings, increases 2025 guidance

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street estimates and sending its stock up about 2% in pre-market trad

Zacks.com on MSN · 15h

Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates

Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago. These figures are adjusted for non-recurring items.

15h

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

10hon MSN

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

14hon MSN

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

11hon MSN

Why Eli Lilly Stock Popped on Thursday

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

12hon MSN

Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

16h

Eli Lilly records over twofold rise in diabetes/ obesity drugs in Q4

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

15h

Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

13hon MSN

Eli Lilly’s Disappointing Quarter Was Already Baked In

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

FierceBiotech9h

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results